Evidence map›Paper›PMID 25859981›Full record

Trial reportPloS one2015

Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.

Jean-Christophe Brisset, Benjamin A Hoff, Thomas L Chenevert, Jon A Jacobson, Jennifer L Boes, Stefanie Galbán, Alnawaz Rehemtulla, Timothy D Johnson, Kenneth J Pienta, Craig J Galbán and 6 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Enhanced Bone Metastases in Skeletally Immature Mice.Tomography (Ann Arbor, Mich.) · 2018
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Jean-Christophe BrissetDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Benjamin A HoffDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Thomas L ChenevertDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Jon A JacobsonDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Jennifer L BoesDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Stefanie GalbánDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Alnawaz RehemtullaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Timothy D JohnsonDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States of America.
Kenneth J PientaDivision of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Craig J GalbánDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Charles R MeyerDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Timothy SchakelDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands.
Klaas NicolayDepartment of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
Ajjai S AlvaDivision of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Maha HussainDivision of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, United States of America.
Brian D RossDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America.
Michigan United · USUniversity of Michigan–Ann Arbor · USEindhoven University of Technology · NLUniversity Medical Center Utrecht · NL

Funding

Presurgical Planning with Optimized Verbalized Speech Activation Studies inP01CA087634 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLAND, PEYTON H · 2002 to 2013
$14.8M
Image Biomarker Development for TreatmentEfficacy of Prostate Cancer to the BoneR01CA136892 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2009 to 2012
$2.1M
NCI NIH HHS P01 CA087634NCI NIH HHS P01CA087634NCI NIH HHS R01 CA136892NCI NIH HHS R01CA136892
6 · The paper itself

Abstract

Bone metastasis occurs for men with advanced prostate cancer which promotes osseous growth and destruction driven by alterations in osteoblast and osteoclast homeostasis. Patients can experience pain, spontaneous fractures and morbidity eroding overall quality of life. The complex and dynamic cellular interactions within the bone microenvironment limit current treatment options thus prostate to bone metastases remains incurable. This study uses voxel-based analysis of diffusion-weighted MRI and CT scans to simultaneously evaluate temporal changes in normal bone homeostasis along with prostate bone metatastsis to deliver an improved understanding of the spatiotemporal local microenvironment. Dynamic tumor-stromal interactions were assessed during treatment in mouse models along with a pilot prospective clinical trial with metastatic hormone sensitive and castration resistant prostate cancer patients with bone metastases. Longitudinal changes in tumor and bone imaging metrics during delivery of therapy were quantified. Studies revealed that voxel-based parametric response maps (PRM) of DW-MRI and CT scans could be used to quantify and spatially visualize dynamic changes during prostate tumor growth and in response to treatment thereby distinguishing patients with stable disease from those with progressive disease (p<0.05). These studies suggest that PRM imaging biomarkers are useful for detection of the impact of prostate tumor-stromal responses to therapies thus demonstrating the potential of multi-modal PRM image-based biomarkers as a novel means for assessing dynamic alterations associated with metastatic prostate cancer. These results establish an integrated and clinically translatable approach which can be readily implemented for improving the clinical management of patients with metastatic bone disease.

Indexed as

AnimalsAntineoplastic AgentsBone DensityBone NeoplasmsDiffusion Magnetic Resonance ImagingDiphosphonatesDisease Models, AnimalDocetaxelHumansMaleMiceMultimodal ImagingOsteoblastsOsteolysisProstatic NeoplasmsTaxoidsAntineoplastic AgentsDiphosphonatesDocetaxelTaxoids

Identifiers

PMID25859981
PMCPMC4393258
OpenAlexW2319900733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.